[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"the-eradication-rates-of-helicobacter-pylori\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:the-eradication-rates-of-helicobacter-pylori":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100529010","phase-4-standard-or-short-course-vonoprazan-non-bismuth-triple-therapy-or-high-dose-dual-therapy-versus-rabeprazole-bismuth-quadruple-therapy-for-primary-helicobacter-pylori-eradication-100529010",false,"NCT06168214","Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication: A Single-center, Randomised, Controlled Trial.","Inclusion Criteria:\n\n* Age 18-70 years, regardless of sex; chronic gastritis, peptic ulcer or dyspeptic symptoms, clear Hp infection (positive 13C-urea breath test); voluntary Hp eradication treatment; women of childbearing age are required to use a medically desirable form of contraception during the trial and for 1 month after the trial.\n\nExclusion Criteria:\n\n* Have contraindications to the study drug or are allergic to the study drug; have taken a PPI within 2 weeks and an antibiotic or bismuth within 4 weeks; pregnant and lactating women; and Have undergone upper gastrointestinal surgery; refluse to sign the informed consent document.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},1404,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection. The main questions it aims to answer are:\n\n* Main indicators: the eradication rate of Helicobacter pylori for eradication.\n* Secondary indicators: symptomatic relief rate at 2 weeks after treatment and 4 weeks after the end of treatment; compliance and adverse reactions during treatment.",[28],"the Eradication Rates of Helicobacter Pylori",[30],"Helicobacter pylori ; Vonoprazan","RECRUITING","2024-08-09",{"date":34,"type":35},"2024-08-13","ACTUAL",{"date":37,"type":35},"2023-09-04",{"date":39,"type":22},"2024-12-25",{"name":41,"class":42},"Xijing Hospital of Digestive Diseases","OTHER"]